Ferring Gets Extra Exclusivity As Judge Reverses FDA Win
The U.S. Food and Drug Administration must retroactively grant Ferring Pharmaceuticals Inc. five years of exclusivity for its colonoscopy drug Prepopik under a new agency policy controlling how much exclusivity multiple-ingredient...To view the full article, register now.
Already a subscriber? Click here to view full article